Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Baum

Showing results (131-140 of 143) with videos related to

Pageof 15
Sort By:
Plos Pathogens|October 3, 2013
Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized miceIlona Hauber, Helga Hofmann-Sieber, Jan Chemnitz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 15, 2007
Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trialsElke Will, Jeff Bailey, Todd Schuesler, et al.
Cancer Research|August 5, 2008
Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cellsMichael D Milsom, Moran Jerabek-Willemsen, Chad E Harris, et al.
Blood|November 23, 2006
Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathwaysOlga S Kustikova, Hartmut Geiger, Zhixiong Li, et al.
Human Gene Therapy|November 25, 2010
Cell and virus genetics at the roots of gene therapy, retrovirology, and hematopoietic stem cell biology: Wolfram Ostertag (1937-2010)Carol Stocking, Manuel Grez, Boris Fehse, et al.
Molecular Therapy. Methods & Clinical Development|May 28, 2015
Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitorOrit Wolstein, Maureen Boyd, Michelle Millington, et al.
The Journal of Allergy and Clinical Immunology|August 14, 2014
Successful RAG1-SCID gene therapy depends on the level of RAG1 expressionKarin Pike-Overzet, Christopher Baum, Robbert G M Bredius, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 14, 2011
Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioningMarshall W Huston, Niek P van Til, Trudi P Visser, et al.
Nature Medicine|June 26, 2012
Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicityHartmut Geiger, Snehalata A Pawar, Edward J Kerschen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 2, 2012
Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapyJacqueline Corrigan-Curay, Odile Cohen-Haguenauer, Marina O'Reilly, et al.
Pageof 15

Showing results (131-140 of 143) with videos related to

Sort By:
Pageof 15
Plos Pathogens|October 3, 2013
Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized miceIlona Hauber, Helga Hofmann-Sieber, Jan Chemnitz, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 15, 2007
Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trialsElke Will, Jeff Bailey, Todd Schuesler, et al.
Cancer Research|August 5, 2008
Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cellsMichael D Milsom, Moran Jerabek-Willemsen, Chad E Harris, et al.
Blood|November 23, 2006
Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathwaysOlga S Kustikova, Hartmut Geiger, Zhixiong Li, et al.
Human Gene Therapy|November 25, 2010
Cell and virus genetics at the roots of gene therapy, retrovirology, and hematopoietic stem cell biology: Wolfram Ostertag (1937-2010)Carol Stocking, Manuel Grez, Boris Fehse, et al.
Molecular Therapy. Methods & Clinical Development|May 28, 2015
Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitorOrit Wolstein, Maureen Boyd, Michelle Millington, et al.
The Journal of Allergy and Clinical Immunology|August 14, 2014
Successful RAG1-SCID gene therapy depends on the level of RAG1 expressionKarin Pike-Overzet, Christopher Baum, Robbert G M Bredius, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 14, 2011
Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioningMarshall W Huston, Niek P van Til, Trudi P Visser, et al.
Nature Medicine|June 26, 2012
Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicityHartmut Geiger, Snehalata A Pawar, Edward J Kerschen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 2, 2012
Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapyJacqueline Corrigan-Curay, Odile Cohen-Haguenauer, Marina O'Reilly, et al.
Pageof 15